Searched for
INTAS BIOPHARMACEUTICAL LTD
Creador frontrunner to buy Tata Capital's stake in packaging coTata Capital to exit its 5-year old investment in Shriji Polymers.- Keddara, Creador join in race for Tata Capital's stake in Shriji PolymersFinal bids are likely to be submitted by 31 March and the company is expected to be valued at Rs.1000 - 1200 crore, said two people aware o...
- Desi pharma companies top in biosimilars globallyBiosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.
- Biologics enter top selling drugs’ listBiologics, also called biopharmaceuticals, have revolutionised treatment in chronic and serious illnesse and nudged traditional drugs out o...
- Intas cuts Razumab supplies after adverse eye reactionsRazumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25 per cent cheaper than the innovator drug marketed by Novart...
- Intas Pharmaceutical launches low cost drug 'Mabtas' for cancer treatmentIntas Pharmaceutical today said it has launched 'Mabtas' a new low cost drug for treating cancer in India.
- Intas ex-employee objects to amalgamation planAn affidavit of objection challenging Intas' amalgamation was filed by Mani Iyer, a former executive director of Intas Biopharmaceuticals, ...
- Biosimilars to replace 70% of chemical drugs in 2 decadesBiosimilars products are set to replace some 70% of global chemical drugs over the next couple of decades on account of safety parameters.
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
- Reliance Life Sciences bets big on biosimilarsReliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a hug...
- Glenmark Pharma plans to list its generics subsidiaryGlenmark Pharmaceuticals is planning to list its generics subsidiary - Glenmark Generics - and has filed a draft red herring prospectus wit...
- US amendment may leave Indian biopharma cos shaken & stirredIndian biopharmaceutical companies are likely to face more hurdles in the US.
- PE investments in pharma touch $400 mPrivate Equity (PE) investments in the domestic healthcare and pharma industry have touched around $400 million during the first nine month...
- FIPB clears FDI plans worth Rs 1,257 croreThe Foreign Investment Promotion Board (FIPB) has cleared 14 FDI proposals involving FDI worth Rs 1,257 crore, including those of Mauritius...
- Panacea, Intas plan biosimilar launchJoining Indian pharma majors who are targeting the $65-billion global biotech drug market.
- Mauritius-based FIIs to pick up 47% in Intas' biotech armA clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...
- Gujarat next biotech hub, number of cos up 50%Big pharma companies such as Zydus Healthcare plans to focus on biotech in a big way.
- Intas mfg unit gets EU-GMP certificationIntas Biopharmaceuticals Ltd (IBPL) has received European Union-good manufacturing practices (EU-GMP) certification for its manufacturing f...
- ICICI Venture buys out US R&D firmICICI Venture has made the first buyout by an Indian private equity firm in the international market.
Load More
